NX:NYSEQuanex Building Products Corporation Analysis
Data as of 2026-04-21 - not real-time
$20.64
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Quanex Building Products (NX) is trading around $20.64, well above its DCF‑derived fair value of roughly $10, indicating a material overvaluation. Technicals show a bullish MACD histogram (+0.28) and an RSI of 63, yet price sits just below the recent resistance of $21.33 and above the support at $16.92, while volume has been trending down, suggesting limited upside momentum. The stock’s beta of ~1.85 and 30‑day volatility near 48% point to pronounced price swings, and the “Extreme Greed” sentiment index (86) may be inflating demand.
Fundamentally, the company posts negative profit margins (‑13 %) and a -28 % ROE, carries a high debt‑to‑equity ratio of 122 %, and its trailing EPS is negative, though forward EPS is modestly positive (2.3). The dividend yield of 1.53 % is backed by an 86 % payout, raising sustainability concerns given the earnings backdrop. Combined with a neutral trend direction and a sizable max drawdown of ~‑50 %, the risk‑reward profile remains tilted toward caution.
Fundamentally, the company posts negative profit margins (‑13 %) and a -28 % ROE, carries a high debt‑to‑equity ratio of 122 %, and its trailing EPS is negative, though forward EPS is modestly positive (2.3). The dividend yield of 1.53 % is backed by an 86 % payout, raising sustainability concerns given the earnings backdrop. Combined with a neutral trend direction and a sizable max drawdown of ~‑50 %, the risk‑reward profile remains tilted toward caution.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bullish MACD and RSI indicating near‑term momentum
- Recent news‑driven 5.3% price jump on geopolitical optimism
- Proximity to resistance level with decreasing volume
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- High debt load and negative profitability metrics
- DCF fair value far below current market price
- Dividend yield potentially unsustainable given earnings
Long Term
> 3 yearsCautious
Model confidence: 4/10
Key Factors
- Structural earnings weakness and negative ROE
- Elevated volatility and beta implying price instability
- Valuation gap and sector cyclicality limiting upside
Key Metrics & Analysis
Financial Health
Revenue Growth2.30%
Profit Margin-13.00%
P/E Ratio9.0
ROE-28.19%
ROA3.91%
Debt/Equity122.22
P/B Ratio1.3
Op. Cash Flow$157.2M
Free Cash Flow$85.7M
Industry P/E31.0
Technical Analysis
TrendNeutral
RSI63.0
Support$16.92
Resistance$21.33
MA 20$18.80
MA 50$19.31
MA 200$17.31
MACDBullish
VolumeDecreasing
Fear & Greed Index86.11
Valuation
Fair Value$9.97
Target Price$28.75
Upside/Downside39.32%
GradeOvervalued
TypeValue
Dividend Yield1.53%
Risk Assessment
Beta1.85
Volatility47.92%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.